Hilton Santa Fe Historic Plaza Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2007



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

PI 3-Kinase Signaling Pathways in Disease (B8)


Organizer(s) Peter M. Finan and Lewis C. Cantley
February 15—20, 2007
Hilton Santa Fe Historic Plaza Hotel • Santa Fe, New Mexico USA
Abstract Deadline: Oct 16, 2006
Late Abstract Deadline: Nov 15, 2006
Scholarship Deadline: Oct 16, 2006
Early Registration Deadline: Dec 15, 2006

Supported by Merck Research Laboratories

Summary of Meeting:
The PI 3-kinase signaling pathway is emerging as a promising therapeutic target in a number of human diseases including cancer, inflammation and heart disease. Mutations in the PIK3CA gene and the deletion of lipid phosphatase, PTEN, are widespread in many tumors. Mouse models which target individual PI 3-kinase isoforms have shed light on the roles of these enzymes in immune cell function, mast cell degranulation and leukocyte migration. One of the most exciting developments in this field is the discovery of new PI 3-kinase inhibitors. However, identifying the indications that will provide the best opportunity to develop these inhibitors is the subject of intense debate. This meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI 3-kinase pathway in disease, drawing on human pathophysiology and genetics, mouse models and preclinical data with new PI 3-kinase inhibitors.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


THURSDAY, FEBRUARY 15

15:00—19:30
Registration

Promenade
18:30—19:30
Refreshments

Promenade
19:30—20:30
Keynote Address: Targeting the PI3K Pathway
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
Lewis C. Cantley, Weill Cornell Medicine, USA
Control of Cell Growth by LKB1/AMPK versus PI3K/AKT: Implications for Cancer and Diabetes


FRIDAY, FEBRUARY 16

07:00—08:00
Breakfast

Chamisa
08:00—11:00
PI 3-Kinase Signaling I
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Peter M. Finan, Epidarex Capital, UK

Len R. Stephens, Babraham Institute, UK
Signaling via PI3Ks

Jan Domin, Imperial College London, UK
Activation and Function of Class II Phosphoinositide 3-Kinase Enzymes

Emilio Hirsch, Fondazione per la Ricerca Biomedica – ONLUS, Italy
What Function for PI3Kbeta?

Marco Falasca, Barts & The London School of Medicine & Dentistry, UK
Short Talk: Emerging Roles of Phosphatidylinositol-3-Phosphate as a Dynamic Intracellular Second Messenger

Takehiko Sasaki, Akita University School of Medicine, Japan
Short Talk: Control of Chemotaxis by PI3Ks and PtdIns(3,4,5)P3 Phosphatases

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Ortiz
13:00—22:00
Poster Viewing

Ortiz
16:30—17:00
Coffee Available

Promenade
17:00—19:00
PI 3-Kinase Signaling II
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Len R. Stephens, Babraham Institute, UK

Dario Alessi, University of Dundee, UK
PDK1 Signaling

Brendan D. Manning, Harvard School of Public Health, USA
Signal Integration and Feedback Inhibition Within the TSC-mTORC1 Signaling Network

Bruno D. Fonseca, University of British Columbia, Life Sciences Institute, Canada
Short Talk: PRAS40, a Novel Raptor Binding Partner, is Essential for the Function of the mTORC1 Complex

Andreas Androutsellis-Theotokis, NINDS, National Institutes of Health, USA
Short Talk: STAT3-Ser727: A Stem Cell Target for Cancer and Regeneration, Downstream of PI3 Kinase

19:00—20:00
Social Hour with Lite Bites

Ortiz/Chamisa
19:30—22:00
Poster Session 1

Ortiz/Chamisa

SATURDAY, FEBRUARY 17

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Dissecting PI 3-Kinase Isoform Specificity
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Matthias P. Wymann, University of Basel, Switzerland

Bart Vanhaesebroeck, University College London, Cancer Institute, UK
Dissecting PI 3-kinase Function Using Genetically Modified Mice

Kevan M. Shokat, University of California, San Francisco, USA
PI3K Target Validation Using a Matrix of Selective Small Molecule PI3K Inhibitors

John Doukas, Vical Incorporated, USA
PI3K gamma/delta Inhibitors as Therapeutics for Inflammatory-Based Diseases

Christian Rommel, F. Hoffmann-La Roche Ltd, Switzerland
PI 3-kinase gamma Inhibitors

Peter Lamb, Exelixis, USA
Short Talk: Characterization of Selective Inhibitors of Class I and Class III PI3 Kinases

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Ortiz
13:00—22:00
Poster Viewing

Ortiz
16:30—17:00
Coffee Available

Promenade
17:00—19:00
PI 3-Kinase Signaling in the Immune System
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Bart Vanhaesebroeck, University College London, Cancer Institute, UK

Matthias P. Wymann, University of Basel, Switzerland
PI3K - Context-dependent Signaling

David A. Fruman, University of California, Irvine, USA
Role of Class IA PI3K in T Cell Function and Autoimmunity

Klaus Okkenhaug, Babraham Institute, UK
The PI3K p110delta Regulates T Cell Differentiation and Regulation

Subha Krishnan, Indiana University School of Medicine, USA
Short Talk: Differential Role of p85á and p85â Regulatory Subunits of Class IA PI-3Kinase in Mast Cell Growth and Differentiation

19:00—20:00
Social Hour with Lite Bites

Ortiz/Chamisa
19:30—22:00
Poster Session 2

Ortiz/Chamisa

SUNDAY, FEBRUARY 18

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Crosstalk to Other Pathways
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* George Thomas, University of Cincinnati, USA

Brian A. Hemmings, Friedrich Miescher Institute, Switzerland
Effectors Downstream of PI 3-Kinase: AKT/PKB

Yan Luo, Abbott Laboratories, USA
Potent and Selective Inhibitors of Akt Delay Tumor Growth and Sensitize Tumors to Chemotherapy in vivo

Heidi A. Lane, Basilea Pharmaceutica International Ltd., Switzerland
The mTOR Inhibitor RAD001 (Everolimus): A Promising Therapeutic for the Treatment of Human Cancers

Igor Vivanco, Institute of Cancer Research, UK
Short Talk: Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Ortiz
13:00—22:00
Poster Viewing

Ortiz
16:30—17:00
Coffee Available

Promenade
17:00—19:00
PI 3-Kinase Signaling and Control of Metabolism
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Lewis C. Cantley, Weill Cornell Medicine, USA

George Thomas, University of Cincinnati, USA
The Role of the Nutrient Input in TSC1/2-Rheb Mediated mTOR signaling

Morris J. Birnbaum, Pfizer Inc., USA
Regulation of Glucose and Lipid Metabolism by Akt/PKB

Takashi Kadowaki, University of Tokyo, Japan
Insulin Signaling

Cheryl L. Walker, Baylor College of Medicine, USA
Short Talk: Activation of AMPK Signaling in TSC2-Deficient Cells Regulates p27 Localization and Function

19:00—20:00
Social Hour with Lite Bites

Ortiz/Chamisa
19:30—22:00
Poster Session 3

Ortiz/Chamisa

MONDAY, FEBRUARY 19

07:00—08:00
Breakfast

Chamisa
08:00—11:00
PI 3-Kinase Signaling and Cancer I
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Paul Workman, Institute of Cancer Research, UK

Thomas M. Roberts, Dana-Farber Cancer Institute, USA
Targeting PI3 Kinase Isoforms in Cancer

Paul S. Mischel, University of California, San Diego, USA
mTOR Inhibitors in Glioblastoma

Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
PTEN and Tumorigensis

Levi A. Garraway, Eli Lilly and Company, USA
Somatic Alterations of PTEN and PIK3CA Elicit Distinct Cancer Phenotypes

Surbhi Gupta, ,
Short Talk: The Interaction of Ras with p110alpha is Required for Ras-Driven Tumorigenesis and for Normal Lymphatic Development

09:20—09:40
Coffee Break

Promenade
16:30—17:00
Coffee Available

Promenade
17:00—19:00
PI 3-Kinase Signaling and Cancer II
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Peter M. Finan, Epidarex Capital, UK

Jonathan M. Backer, Albert Einstein College of Medicine, USA
Mechanism of Oncogenic Deregulation of Class IA PI 3-Kinases

Paul Workman, Institute of Cancer Research, UK
Drugging the PI3 Kinome for Cancer Treatment

Carlos García-Echeverría, Sanofi-Aventis, France
Blocking the PI3K/PKB Signaling Pathway in Tumor Cells: A Challenging and Ardous Drug Discovery Enterprise

Lewis C. Cantley, Weill Cornell Medicine, USA
Closing Statement

19:00—20:00
Social Hour with Lite Bites

Mesa C
20:00—23:00
Entertainment

Mesa C

TUESDAY, FEBRUARY 20

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 DK076500-01




We gratefully acknowledge additional support for this conference from:

Cell Signaling Technology, Inc. Educational donation provided by Amgen

EMD Millipore

Genentech, Inc.
GlaxoSmithKline Oncology Merck Research Laboratories
Novartis Institutes for BioMedical Research UCB Celltech

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Abbott Laboratories


Novartis Pharma AG


TargeGen, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676